Comparative Analysis of Quality of Life in Anxiety Disorder Patients Receiving Zolpidem and Escitalopram at Goeteng Taroenadibrata General Hospital Using the EQ-5D-5L Instrument
Article metrics
OJS usage and citation sourcesViews and downloads are recorded by OJS; statistics processing may be delayed. A dash means the source count is unavailable. Search Google Scholar
Article Sidebar
Saskia Nur Ubay, Khamdiyah Indah Kurniasih, Fauziah Fauziah (2025). Comparative Analysis of Quality of Life in Anxiety Disorder Patients Receiving Zolpidem and Escitalopram at Goeteng Taroenadibrata General Hospital Using the EQ-5D-5L Instrument. Journal of Pharmaceutical and Sciences, JPS Volume 8 Nomor 4 (2025). https://doi.org/10.36490/journal-jps.com.v8i4.1083
Main Article Content
Abstract
Anxiety disorders are among the most common mental health problems in society and can affect patients’ quality of life. This study provides a comparative overview of the quality of life of patients with anxiety disorders at Goeteng Taroenadibrata Regional General Hospital who received Zolpidem or Escitalopram therapy. The purpose of this study was to determine whether there was a significant difference in the quality of life between patients using Zolpidem and those using Escitalopram. This study was a descriptive quantitative study using a cross-sectional approach. The study population consisted of patients with anxiety disorders at Goeteng Taroenadibrata Regional General Hospital, with a sample of 60 patients divided into two groups based on the therapy received, namely Zolpidem (30 patients) and Escitalopram (30 patients). Quality of life was measured using the EQ-5D-5L instrument. The results showed that 53.3% of patients in the Zolpidem group were male, while 66.7% of those in the Escitalopram group were female. In terms of age, most patients were over 60 years old, both in the Zolpidem group (83.3%) and the Escitalopram group (80.0%). In addition, the majority of patients in both groups had been undergoing treatment for more than six months (66.7%), with 20 patients in each therapy group. Statistical analysis using the Mann-Whitney test showed no significant difference in the quality of life between patients receiving Zolpidem and those receiving Escitalopram, with a p-value greater than 0.05.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Rabbani M, Salahuddin Andi Palloge, Han Fransiskus Susanto, Nur Isra, Irma Santy. Karakteristik dan Faktor Risiko Pasien Gangguan Kecemasan Tahun 2022. Fakumi Med J J Mhs Kedokt 2024;4:220–30. https://doi.org/10.33096/fmj.v4i3.412.
Rositah DSA, Fuji Ayu D, Ivada O, Nuraeni P. Penyalahgunaan Obat Sedatif serta Dampak Pengguna terhadap Kesehatan dan Sosial: Literature Review 2022.
PGIMS, Rohtak, Haryana, India., Malhotra P. Combined use of sedatives and antidepressant mandates rational approach. J Clin Images Med Case Rep 2023;4. https://doi.org/10.52768/2766-7820/2295.
Jiwandono S. Gambaran Penggunaan Obat Antidepressant Terhadap Penderita Gangguan Depresi di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Periode Januari-Juni 2017 2022;3.
Yumassik AM, Azizah N, Illahi FS, Wahyuni A, Aisyah N, Soraya S. Hubungan Kualitas Hidup Pasien Hipertensi Dengan Karakteristik Demografi Menggunakan Instrumen EQ-5D DI Puskesmas S. Parman Kota Banjarmasin. J Insan Farm Indones 2024;7:1–8. https://doi.org/10.36387/jifi.v7i1.1932.
Raffli A, Yuswar MA, Rizkifani S. Pengukuran Kualitas Hidup Penderita Hipertensi Menggunakan Instrumen EQ-5D-5L. J Syifa Sci Clin Res 2023;5. https://doi.org/10.37311/jsscr.v5i1.18103.
Hamida N, Ulfa M, Haris RNH, Endarti D, Wiedyaningsih C. Pengukuran Kualitas Hidup Pasien Program Pengelolaan Penyakit Kronis (Prolanis) di Puskesmas Menggunakan Instrumen EQ-5D-5L. Maj Farm 2019;15:67. https://doi.org/10.22146/farmaseutik.v15i2.46328.
Avelina Y, Natalia IY. Hubungan Tingkat Kecemasan Dengan Kualitas Hidup Pasien Hipertensi yang Sedang Menjalani Pengobatan Hipertensi di Desa Lenandareta Wilayah Kerja Puskesmas Paga 2020.
Oktamarin L, Kurniati F, Sholekhah M, Nurjanah S, Oktaria SW, Sukmawati S, et al. Gangguan Kecemasan (Axiety Disorder) Pada Anak Usia Dini. J Multidisipliner Bharasumba 2022;1:119–34. https://doi.org/10.62668/bharasumba.v1i02.192.
Rahman Q, Oktavilantika DM. Profil Penggunaan Obat Antidepresan Pada Pasien Gangguan Ansietas Di Rumah Sakit Bhayangkara Indramayu Pada Tahun 2021. J Farm Dan Farmakoinformatika 2023;1:113–25. https://doi.org/10.35760/jff.2023.v1i2.8728.
Patel D, Steinberg J, Patel P. Insomnia in the Elderly: A Review. J Clin Sleep Med 2018;14:1017–24. https://doi.org/10.5664/jcsm.7172.
Edinoff AN, Wu N, Ghaffar YT, Prejean R, Gremillion R, Cogburn M, et al. Zolpidem: Efficacy and Side Effects for Insomnia. Health Psychol Res 2021;9. https://doi.org/10.52965/001c.24927.
Lestari SAR, Puspitasari IM, Zakiyah N, Gunawan E. Analisis Efektivitas Biaya Escitalopram dan Fluoksetin Dibandingkan dengan Sertralin untuk Gangguan Depresi Mayor di Salah Satu Klinik di Kota Bandung 2022;11.
Feng R, Ma R, Wang P, Ji X, Zhang Z, Li M, et al. Efficacy of escitalopram for poststroke depression: a systematic review and meta-analysis. Sci Rep 2022;12:3304. https://doi.org/10.1038/s41598-022-05560-w.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 2021;384:1402–11. https://doi.org/10.1056/NEJMoa2032994.
Yuniarsih SM, Nugroho ST, Hasanah N. Kajian Kecemasan Dan Kualitas Hidup Lansia Di Masa Pandemi Covid-19 2021;9.
Firmansyah F, Tiara Tri Agustini, Tri Murti Andayani. Health Related Quality Of Life: Chronic Kidney Disease Dengan Hemodialisa Menggunakan Instrumen EQ-5D-5L di Pekanbaru. J Ilm Manuntung 2022;8:55–62. https://doi.org/10.51352/jim.v8i1.487.
Andayani TM, Endarti D, Kristina SA, Rahmawati A. Perbandingan EQ-5D-5L dan SF-6D Untuk Mengukur Index Utility Kesehatan Pada Populasi Umum di Yogyakarta. J Manaj dan Pelayanan Farm J Manag Pharm Pract 2020;10:35. https://doi.org/10.22146/jmpf.49462.
Skarayadi O, Prasodjo MD, Sutjiatmo AB. Pengukuran Kualitas Hidup Pasien Hipertensi dengan Metode EQ-5D-5L di salah satu Rumah Sakit di Bandung 2023;1.
Sandin K, Shields G, Gjengedal RGH, Osnes K, Bjørndal MT, Reme SE, et al. Responsiveness to change in health status of the EQ-5D in patients treated for depression and anxiety. Health Qual Life Outcomes 2023;21:35. https://doi.org/10.1186/s12955-023-02116-y.
Purba FD, Hunfeld JAM, Iskandarsyah A, Fitriana TS, Sadarjoen SS, Ramos-Goñi JM, et al. The Indonesian EQ-5D-5L Value Set. PharmacoEconomics 2017;35:1153–65. https://doi.org/10.1007/s40273-017-0538-9.
Machado FV, Louzada LL, Cross NE, Camargos EF, Dang-Vu TT, Nóbrega OT. More than a quarter century of the most prescribed sleeping pill: Systematic review of zolpidem use by older adults. Exp Gerontol 2020;136:110962. https://doi.org/10.1016/j.exger.2020.110962.
Mochcovitch MD, Da Rocha Freire RC, Garcia RF, Nardi AE. Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review. Clin Drug Investig 2017;37:737–43. https://doi.org/10.1007/s40261-017-0528-x.
Janjic V, Radmanovic B, Bukumiric Z, Dejanovic SD, Muric N, Borovcanin M. Quality of Life in Primary Insomnia: Three-week Treatment With Zolpidem Vs. Lorazepam. Serbian J Exp Clin Res 2017;18:231–7. https://doi.org/10.1515/sjecr-2016-0077.
Dzevlan A, Redzepagic R, Hadzisalihovic M, Curevac A, Masic E, Gelo E, et al. Quality of Life Assessment in Antidepressant Treatment of Patients with Depression and/or Anxiety Disorder. Mater Socio Medica 2019;31:14. https://doi.org/10.5455/msm.2019.31.14-18.
Tondok SB, Watu E, Wahyuni W. Validitas instrumen European Qualitiy of Life (EQ-5D-5L) Versi Indonesia untuk menilai kualitas hidup penderita tuberkulosis. Holistik J Kesehat 2021;15:267–73. https://doi.org/10.33024/hjk.v15i2.4759.